Log In
BCIQ
Print this Print this
 

Anti-CD40L Fab, Dapirolizumab pegol (CD40L, CDP7657)

  Manage Alerts
Collapse Summary General Information
Company Biogen Inc.
DescriptionFab antibody targeting CD40 ligand (CD40L)
Molecular Target CD40 ligand (CD40L) (CD40LG) (CD154)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationLupus
Indication DetailsTreat systemic lupus erythematosus (SLE)
Regulatory Designation
PartnerNektar Therapeutics;
UCB Group

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/02/2012

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today